PCA
IDXX icon

Providence Capital Advisors’s Idexx Laboratories IDXX Stock Holding History

Providence Capital Advisors’s Portfolio IDXX Stock Details IDXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-46
Closed -$9K – 252
2018
Q1 		$9K Buy
+46
New +$8.49K 0.01% 185

Other funds holding IDXX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FEF
Fundsmith Equity Fund Stamford, Connecticut $13.4B AUM
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Providence Capital Advisors's IDXX Position: Q2 2018 in Review

Providence Capital Advisors sold out of Idexx Laboratories (IDXX) in Q2 2018, closing a stake of 46 shares — an estimated $9K sold.

Providence Capital Advisors first reported a position in IDXX in Q1 2018 and held it in 1 quarter. The position peaked at $9K in Q1 2018. 664 funds tracked by Wall St. Rank hold IDXX as of Q2 2018.

  • Providence Capital Advisors reported no remaining Idexx Laboratories position as of Q2 2018 after selling out during the quarter.
  • Providence Capital Advisors sold 46 Idexx Laboratories shares in Q2 2018, an estimated $9K.
  • Providence Capital Advisors first reported a position in Idexx Laboratories in Q1 2018 and held it in 1 quarter.
  • Providence Capital Advisors's Idexx Laboratories position peaked at $9K in Q1 2018.
  • 664 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2018.

Based on Providence Capital Advisors's 13F filing for Q2 2018, filed 8 Aug 2018.